spiermetabolisme Loss of muscle mass
Conditions
Interventions
The intervention consist of a single test day during which the subjects will
receive a drink containing 20 gram intrinsically labelled casein followed by
local administration of insulin or saline (p
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 24 healthy, non obese (BMI
Exclusion criteria
Exclusion criteria: Hemoglobine level below 8.0 mmol/L Cardiac abnormalities Coagulation disorders Vascular diseases Obesity (BMI > 30 kg*m2) Diabetes mellitus type 1 and type 2 Glucose intolerance HbA1c > 7.0% Diagnosed impaired renal or liver function Smoking All co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthrosis, arthritis, spasticity/rigidity, all neurological disorders and paralysis) Cancer Hypertension Acute or chronic pulmonary diseases Allergy for lidocain or iodine Use of NSAIDs and acetylsalicylic acid Patients suffering from PKU (Phenylketonuria) Infectious disease Participation in any regular exercise program Unstable body weight over the last 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint: Muscle protein synthesis rate, expressed as fractional synthetic rate (FSR). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints: Rate of protein digestion and absorption, whole body protein balance, femoral and leg blood flow and microvascular perfusion. | — |
Countries
Netherlands
Outcome results
None listed